Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Victoza

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Victoza (liraglutide) is a modern antidiabetic drug of GLP1 (glucagone like peptide) analogue group; since 2009 registered in… Expand
2015
2015
AIMS The ROOTS study was an observational study to evaluate the effectiveness and safety of liraglutide (Victoza(®)), a GLP-1… Expand
Highly Cited
2014
Highly Cited
2014
Two treatment strategies were compared in patients with type 2 diabetes (T2DM) on basal insulin requiring intensification… Expand
Review
2012
Review
2012
Liraglutide (victoza, Novo Nordisk A/S) is human GLP-1 analogue developed by recombinant DNA technology. It is indicated along… Expand
2010
2010
According to the Centers for Disease Control and Prevention (CDC) prevalence data for 2007, diabetes is a chronic and progressive… Expand
  • table 1
  • figure 1
  • table 2
2010
2010
  • 2010
  • Corpus ID: 8576272
WARNING: RISK OF THYROID C-CELL TUMORS See full prescribing information for complete boxed warning. • Liraglutide causes thyroid… Expand
  • table 1
  • table 2
  • table 3
  • figure 1
  • figure 2
2010
2010
  • The Medical letter on drugs and therapeutics
  • 2010
  • Corpus ID: 25800817
Liraglutide (Victoza-Novo Nordisk), a glucagon-like peptide-1 (GLP-1) receptor agonist given by subcutaneous injection, has been… Expand
2010
2010
Liraglutide (Victoza) is a peptide produced by DNA recombinant technology, which presents 97% homology with human glucagon-like… Expand